A mouse model for HIV-1 entry

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 39, 2012, Pages 15859-15864

  Pietzsch, John ^a,b   Gruell, Henning ^a,c   Bournazos, Stylianos ^a   Donovan, Bridget M ^a   Klein, Florian ^a   Diskin, Ron ^d   Seaman, Michael S ^e   Bjorkman, Pamela J ^d   Ravetch, Jeffrey V ^a   Ploss, Alexander ^a   Nussenzweig, Michel C ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS ENTRY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; MACACA; MICE; MICE, TRANSGENIC; VIRUS INTERNALIZATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA;

EID: 84866843530     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1213409109     Document Type: Article

References (78)

1. McElrath MJ, Haynes BF (2010) Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33:542-554.
2. Walker BD, Burton DR (2008) Toward an AIDS vaccine. Science 320:760-764. (Pubitemid 351929619)
3. Mascola JR, Montefiori DC (2010) The role of antibodies in HIV vaccines. Annu Rev Immunol 28:413-444.
4. Stamatatos L, Morris L, Burton DR, Mascola JR (2009) Neutralizing antibodies generated during natural HIV-1 infection: Good news for an HIV-1 vaccine? Nat Med 15: 866-870.
5. Boberg A, et al. (2008) Murine models for HIV vaccination and challenge. Expert Rev Vaccines 7:117-130. (Pubitemid 351357969)
6. Denton PW, Garcia JV (2009) Novel humanized murine models for HIV research. Curr HIV/AIDS Rep 6:13-19.
7. Klatzmann D, et al. (1984) T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312:767-768. (Pubitemid 15195925)
8. Feng Y, Broder CC, Kennedy PE, Berger EA (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272: 872-877. (Pubitemid 26154590)
9. Deng H, et al. (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666. (Pubitemid 26197679)
10. Trkola A, et al. (1996) CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384:184-187. (Pubitemid 26386476)
11. Dragic T, et al. (1996) HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673. (Pubitemid 26197680)
12. Spijkerman IJ, et al. (1995) Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users compared with homosexual men. AIDS 9:1085- 1092.
13. van't Wout AB, et al. (1994) Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 94:2060-2067.
14. Huang Y, et al. (1996) The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2:1240-1243. (Pubitemid 26375409)
15. Liu R, et al. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-377. (Pubitemid 26272077)
16. Hütter G, et al. (2009) Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 360:692-698.
17. Wei X, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46:1896-1905. (Pubitemid 34535213)
18. Seaman MS, et al. (2010) Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84:1439-1452.
19. Browning J, et al. (1997) Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. Proc Natl Acad Sci USA 94:14637-14641. (Pubitemid 28041426)
20. Szymczak AL, et al. (2004) Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 22:589-594. (Pubitemid 38585911)
21. Berkner KL (1988) Development of adenovirus vectors for the expression of heterologous genes. Biotechniques 6:616-629.
22. He TC, et al. (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95:2509-2514.
23. Alemany R, Curiel DT (2001) CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 8:1347-1353. (Pubitemid 32834304)
24. Leissner P, et al. (2001) Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism. Gene Ther 8:49-57. (Pubitemid 32162415)
25. Mizuguchi H, et al. (2002) CAR- or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Ther 9:769-776. (Pubitemid 34679304)
26. Smith T, et al. (2002) In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Mol Ther 5:770- 779.
27. Safran M, et al. (2003) Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol Imaging 2:297-302.
28. Dorner M, et al. (2011) A genetically humanized mouse model for hepatitis C virus infection. Nature 474:208-211.
29. Plotkin SA (2008) Vaccines: Correlates of vaccine-induced immunity. Clin Infect Dis 47: 401-409.
30. Karlsson Hedestam GB, et al. (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6:143-155.
31. Hessell AJ, et al. (2009) Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5:e1000433.
32. Hessell AJ, et al. (2010) Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 84:1302-1313.
33. Hessell AJ, et al. (2009) Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15:951-954.
34. Mascola JR, et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6:207-210. (Pubitemid 30082367)
35. Shibata R, et al. (1999) Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 5:204-210. (Pubitemid 29068528)
36. Trkola A, et al. (2005) Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 11:615-622. (Pubitemid 40868301)
37. Mehandru S, et al. (2007) Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol 81:11016-11031. (Pubitemid 47536075)
38. Haynes BF, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366:1275-1286.
39. Rerks-Ngarm S, et al.; MOPH-TAVEG Investigators (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209-2220.
40. McMichael AJ, Haynes BF (2012) Lessons learned from HIV-1 vaccine trials: New priorities and directions. Nat Immunol 13:423-427.
41. Diskin R, et al. (2011) Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334:1289-1293.
42. Scheid JF, et al. (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633-1637.
43. Zhou T, et al. (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:811-817.
44. Burton DR, et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027. (Pubitemid 24373715)
45. Walker LM, et al.; Protocol G Principal Investigators (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
46. Wardemann H, et al. (2003) Predominant autoantibody production by early human B cell precursors. Science 301:1374-1377. (Pubitemid 37075812)
47. Parren PW, Burton DR (2001) The antiviral activity of antibodies in vitro and in vivo. Adv Immunol 77:195-262. (Pubitemid 33703707)
48. Overbaugh J, Morris L (2012) The antibody response against HIV-1. Cold Spring Harb Perspect Med, 10.1101/cshperspect.a007039.
49. Forthal DN, Moog C (2009) Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 4:388-393.
50. Gauduin MC, Weir R, Fung MS, Koup RA (1998) Involvement of the complement system in antibody-mediated post-exposure protection against human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 14:205-211. (Pubitemid 28084014)
51. Hessell AJ, et al. (2007) Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449:101-104. (Pubitemid 47373775)
52. Horton HM, et al. (2010) Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood 116:3004-3012.
53. Hope TJ (2011) Moving ahead an HIV vaccine: To neutralize or not, a key HIV vaccine question. Nat Med 17:1195-1197.
54. Burton DR, et al. (2011) Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA 108:11181-11186.
55. Scheid JF, et al. (2009) Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:636-640.
56. Mouquet H, et al. (2011) Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PLoS ONE 6:e24078.
57. Wu X, et al.; NISC Comparative Sequencing Program (2011) Focused evolution of HIV- 1 neutralizing antibodies revealed by structures and deep sequencing. Science 333: 1593-1602.
58. Gardner MB (1990) SIV infection of macaques: A model for AIDS vaccine development. Dev Biol Stand 72:259-266.
59. Li J, Lord CI, Haseltine W, Letvin NL, Sodroski J (1992) Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J Acquir Immune Defic Syndr 5:639- 646.
60. Nath BM, Schumann KE, Boyer JD (2000) The chimpanzee and other non-humanprimate models in HIV-1 vaccine research. Trends Microbiol 8:426-431.
61. Berges BK, Rowan MR (2011) The utility of the new generation of humanized mice to study HIV-1 infection: Transmission, prevention, pathogenesis, and treatment. Retrovirology 8:65.
62. Denton PW, et al. (2008) Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 5:e16.
63. Balazs AB, et al. (2012) Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481:81-84.
64. Baenziger S, et al. (2006) Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice. Proc Natl Acad Sci USA 103: 15951-15956. (Pubitemid 44657573)
65. Gorantla S, et al. (2007) Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/- mice. J Virol 81:2700- 2712.
66. Watanabe S, et al. (2007) Humanized NOD/SCID/IL2Rgamma(null) mice transplanted with hematopoietic stem cells under nonmyeloablative conditions show prolonged life spans and allow detailed analysis of human immunodeficiency virus type 1 pathogenesis. J Virol 81:13259-13264. (Pubitemid 350156965)
67. Brainard DM, et al. (2009) Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodefi ciency virus-infected humanized BLT mice. J Virol 83:7305-7321.
68. Mathers BM, et al.; 2007 Reference Group to the UN on HIV and Injecting Drug Use (2008) Global epidemiology of injecting drug use and HIV among people who inject drugs: A systematic review. Lancet 372:1733-1745.
69. Fechner H, et al. (1999) Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther 6:1520-1535. (Pubitemid 29465510)
70. Bergelson JM, et al. (1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320-1323. (Pubitemid 27114163)
71. Tallone T, et al. (2001) A mouse model for adenovirus gene delivery. Proc Natl Acad Sci USA 98:7910-7915. (Pubitemid 32642661)
72. Hurez V, Dzialo-Hatton R, Oliver J, Matthews RJ, Weaver CT (2002) Efficient adeno-virus- mediated gene transfer into primary T cells and thymocytes in a new coxsackie/ adenovirus receptor transgenic model. BMC Immunol 3:4.
73. Edmonds TG, et al. (2010) Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 408: 1- 13.
74. Perez LG, Costa MR, Todd CA, Haynes BF, Montefiori DC (2009) Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: A specific role for antibodies against the membrane-proximal external region of gp41. J Virol 83: 7397-7410.
75. Walker LM, et al.; Protocol G Principal Investigators (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470.
76. Maddon PJ, et al. (1985) The isolation and nucleotide sequence of a cDNA encoding the T cell surface protein T4: a new member of the immunoglobulin gene family. Cell 42:93-104. (Pubitemid 16237560)
77. Morgenstern JP, Land H (1990) Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 18:3587-3596.
78. Robbiani DF, et al. (2008) AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell 135:1028-1038.